| Document |
Document Title |
|
WO/2016/205475A2 |
The application relates to compounds of formula (A): or a salt, solvate, ester, tautomer, amino acide conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, includin...
|
|
WO/2016/194809A1 |
Provided is a Siraitia grosvenorii extract preparation method, whereby it becomes possible to remove an agrochemical selectively and efficiently from a Siraitia grosvenorii extract containing the agrochemical and to collect a Siraitia gr...
|
|
WO/2016/189200A1 |
Method of recovering sterols from tall oil pitch which contains steryl esters. In the method the tall oil pitch is subjected to a transefterification reaction with a lower alcohol in a reaction zone to provide a reaction product mixture ...
|
|
WO/2016/190480A1 |
The present invention relates to: a method for screening a mitochondrial fission controlling agent using a cell treated with a protopanaxadiol (PPD) ginsenocide compound; a composition for screening a mitochondrial fission controlling ag...
|
|
WO/2016/173397A1 |
The present invention relates to a cholic acid derivative, and a preparation method and a medical use thereof. In particular, the present invention relates to a cholic acid derivative with the structure of formula (I), a stereoisomer, or...
|
|
WO/2016/173524A1 |
Disclosed in the present application are the compounds as shown in formulae I, II, III, IV or V, tautomers thereof, stereoisomers thereof or pharmaceutically acceptable salts thereof, and also disclosed is the use thereof in preparing dr...
|
|
WO/2016/176208A1 |
The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
|
|
WO/2016/172553A1 |
Disclosed herein are methods of making ceragnenin compounds for treating, preventing, or diagnosing diseases, disorders, or conditions associated with bacterial or viral infections, cancer, inflammation, and osteogenesis. Ceragenin compo...
|
|
WO/2016/165496A1 |
Disclosed is method for preparing a deoxycholic acid or ester thereof or pharmaceutically acceptable salt thereof. The compound is suitable for removing fat deposition.
|
|
WO/2016/164413A1 |
The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or inc...
|
|
WO/2016/142922A1 |
The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans o...
|
|
WO/2016/144946A1 |
The present invention relates to methods of treating, reducing the risk of, preventing, or alleviating a symptom of a disease or condition associated with changes in bone density, osteoporosis, or an osteopenic disease, or inducing osteo...
|
|
WO/2016/137196A1 |
The present invention relates to a fatty acid-conjugated 7-dehydrocholesterol derivative and a composition for reducing wrinkles and preventing aging containing the same. The fatty acid-conjugated 7-dehydrocholesterol derivative accordin...
|
|
WO/2016/131414A1 |
The present invention relates to a deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising the compound thereof. Specifically, disclosed are a deuterated chenodeoxycholic acid derivative represented by formu...
|
|
WO/2016/123028A1 |
The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these comp...
|
|
WO/2016/107471A1 |
The present invention relates to a chemical and pharmaceutical technology, and in particular to a STAT3 and ERK signal pathway inhibitor and a use thereof. On the one hand, provided is a STAT3 and ERK signal pathway inhibitor. The inhibi...
|
|
WO/2016/107575A1 |
The present invention relates to a crystal form A of obeticholic acid and a preparation method therefor. The crystal form A provided by the present invention has characteristic peaks at 2theta having values of 4.9º±0.2º, 5.2º±0.2º ...
|
|
WO/2016/096988A1 |
The present invention relates to method of extracting cholesterol from milk fat.
|
|
WO/2016/086115A1 |
The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
|
|
WO/2016/079520A1 |
The invention relates to compounds of formula (I), wherein R1, R2, Y, R4 and R5b are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.
|
|
WO/2016/079518A1 |
The invention relates to compounds of formula (I): wherein R1, R2, Y, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.
|
|
WO/2016/079517A1 |
The invention relates to compounds of formula (I), wherein R1, R2, Y, R4 and R5 are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids.
|
|
WO/2016/060276A1 |
The purpose of the present invention is to provide: a mogrol glycosyltransferase; and a method for producing a mogrol glycoside using the enzyme. The present invention provides: a mogrol glycosyltransferase; and a method for producing a ...
|
|
WO/2016/045642A1 |
The invention provides for treating HBV or HDV infection or inhibiting human sodium taurocholate co-transporting polypeptide (hNTCP) with a polymeric bile acid or salt thereof, and pharmaceutical compositions comprising a polymeric bile ...
|
|
WO/2016/045480A1 |
Provided are a compound represented by formula (III) and a preparation method therefor, wherein R1 is a hydroxyl protective group and preferably is MOM; and also provided is a method for preparing obeticholic acid by using the compound. ...
|
|
WO/2016/029888A1 |
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...
|
|
WO/2016/029197A1 |
The disclosure generally relates to compositions and uses thereof to treat vision disorders that affect the normal function of the lens in the eye in a subject having or at risk of developing such vision disorders.
|
|
WO/2016/023082A1 |
H:\dar\Interwoven\NRPortbl\DCC\DAR\8230712_1.doc-12/08/2015 Abstract The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymp...
|
|
WO/2016/015512A1 |
Disclosed is a method for synthesizing 25-hydroxy cholesterol. The method is as below: subjecting 24-dehydrocholesterol derivative as a raw material and a hydroxyl containing reagent to an addition reaction in the presence of a catalyst ...
|
|
WO/2015/195967A1 |
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, Y, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6a, R6b, R7, and R8 are as defined herein. Compounds...
|
|
WO/2015/195962A1 |
Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment...
|
|
WO/2015/184668A1 |
The present invention provides an ergosterol compound, a preparation method therefor, and an application thereof. A molecular formula of the ergosterol compound is C28H44O, a molecular weight is 396.34, and a molecular structure is: (3R,...
|
|
WO/2015/181275A1 |
13073PTWO 56 ABSTRACT The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases. 5
|
|
WO/2015/170341A1 |
The invention discloses an improved cost-effective process for preparation of 7-Dehydrocholesterol of formula I with good yield and purity, comprising:a) epimerizing 7(alpha+beta) bromo protected cholesterol in presence of tetrabutyl amm...
|
|
WO/2015/168636A1 |
Oxysterol-bisphosphonate and oxysterol-alendronic acid compounds, compositions including them, and methods using them for the treatment of bone disorders.
|
|
WO/2015/158163A1 |
The present invention relates to cyclopentanoperhydrophenanthrene framework compounds and a preparation method therefor. The compounds have certain biological activity, can also be used as an intermediate synthon for synthesizing some co...
|
|
WO/2015/137289A1 |
The present invention pertains to spherical water-dispersible amorphous particles having a particle diameter of 10-990 nm and a PDI of 0.01-0.5, wherein the amorphous particles contain an organic compound having a molecular weight of 50-...
|
|
WO/2015/135927A1 |
The invention relates to 2,4,6-octatrienoic acid derivative compounds having general formula (I) (CH3-CH=CH-CH=CH-CH=CH-CO-O-)n-R (I) consisting of esters wherein n = 1, 2, 3 and wherein R is selected from alkyl, aryl or cycloalkyl of a ...
|
|
WO/2015/115796A1 |
The present invention relates to a PEGylated 7-dehydrocholesterol derivative, and a composition for wrinkle alleviation and antiaging, containing the same. The PEGylated 7-dehydrocholesterol derivative, according to the present invention...
|
|
WO/2015/116867A1 |
Provided are labeling reagents and methods of using the reagents for cell uptake measurements. The labeling reagents can be quinone- masked probes including fluorophores and/or luminophores.
|
|
WO/2015/101468A1 |
The present invention relates to a broad spectrum stable sunscreen molecule having the general structure (Formula) where "X" is an organic sunscreen belonging to the UVA class and "Y" is an organic sunscreen belonging to UVB class or vic...
|
|
WO/2015/057047A9 |
The invention relates to a method for the enzymatic synthesis of lithocholic acid oleate and for the efficient purification of same. The lithocholic acid oleate is a molecule that serves as an antimicrobial peptide elicitor and has an in...
|
|
WO/2015/076788A1 |
The present invention relates to pharmaceutical compositions containing muricholic acid-based compounds, as well as methods of treatment, and methods of screening that use these compounds and compositions.
|
|
WO/2015/049657A1 |
The object of the present invention is a new anhydrous polymorphic crystalline form of sodium hyodeoxycholate (NaHDC) named as form II (FII) and the process for preparing it. Such a process makes it possible to obtain sodium hyodeoxychol...
|
|
WO/2015/034010A1 |
The present invention was completed based on the finding that a compound represented by general formula (I) [wherein R1 and R2 independently represent a hydrocarbon group having 1-5 carbon atoms] or a pharmaceutically acceptable salt the...
|
|
WO/2015/019358A1 |
The present invention provides topical compositions comprising fatty acid bile acid conjugates (FABACs). The present invention further provides methods of using the disclosed compositions for preventing, attenuating or treating skin agin...
|
|
WO/2015/017813A2 |
Disclosed are inhibitors of the farnesoid X receptor, for example of formula (I), wherein R1, R2, R4, X, Y, Z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non...
|
|
WO/2014/198992A1 |
Bioinspired antifungal systems. The invention relates to novel systems based on substrates containing covalently bonded ergosterol molecules that can comprise antifungal compounds imitating the joining of the antifungal agent to the wall...
|
|
WO/2014/195950A1 |
Compositions and methods for treating diseases or disorders associated with the metabolic syndrome using conjugates of bile acids with basic amino acids or a decarboxylated amino acid such as agmatine are provided. Further provided are b...
|
|
WO/2014/184271A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein R1 is a hydroxy group and R2, R3, R4, R5, and R6 are as described herein. The present inven...
|
